Pulmatrix and Eos SENOLYTIX Announce Merger to Advance Anti-Aging Therapies

Key Facts

1Pulmatrix and Eos SENOLYTIX announced a definitive merger agreement under which Pulmatrix will acquire Eos.

2The combined company will operate as Eos SENOLYTIX, focusing on mitochondrial therapies for age-related diseases.

3A $19 million financing was secured to advance the lead clinical candidate PTC-2105 for sarcopenia.

Pulmatrix, Inc. (Nasdaq: PULM) and Eos SENOLYTIX have announced a definitive merger agreement to create a combined biotechnology company focused on human healthspan. Following the acquisition of Eos by Pulmatrix, the new entity will operate under the name Eos SENOLYTIX. The strategic move aims to accelerate the development of mitochondrial therapies specifically designed to combat age-related diseases. To support these clinical efforts, the companies have secured $19 million in financing to advance their lead candidate, PTC-2105, for the treatment of sarcopenia. This merger combines specialized expertise in gerotherapeutic peptides to address significant unmet medical needs. Investors view the deal as a positive step for Pulmatrix, providing both the necessary capital and a clear clinical pathway in the high-growth biotech sector.